Article
Oncology
Cathalijne C. B. Post, Jan Willem M. Mens, Marie A. D. Haverkort, Friederike Koppe, Ina M. Jurgenliemk-Schulz, An Snyers, Ellen M. A. Roeloffzen, Eva E. Schaake, Annerie Slot, Tanja C. Stam, Jannet C. Beukema, Hetty A. van den Berg, Ludy C. H. W. Lutgens, Hans W. Nijman, Cornelis D. de Kroon, Judith R. Kroep, Anne M. Stiggelbout, Carien L. Creutzberg
Summary: The study found a significant difference in the minimally desired survival benefits between patients and clinicians when choosing chemoradiotherapy for high-risk endometrial cancer. Both patients and clinicians considered survival benefits the most important factor during decision making, followed by long-term symptoms. Older patients with comorbidities had lower preference for chemoradiotherapy, while patients with better numeracy skills or previous chemoradiotherapy history had a higher preference.
GYNECOLOGIC ONCOLOGY
(2021)
Article
Medicine, General & Internal
Heather Wakelee, Moishe Liberman, Terufumi Kato, Masahiro Tsuboi, Se-Hoon Lee, Shugeng Gao, Ke-Neng Chen, Christophe Dooms, Margarita Majem, Ekkehard Eigendorff, Gaston L. Martinengo, Olivier Bylicki, Delvys Rodriguez-Abreu, Jamie E. E. Chaft, Silvia Novello, Jing Yang, Steven M. M. Keller, Ayman Samkari, Jonathan D. D. Spicer
Summary: Among patients with resectable early-stage NSCLC, perioperative pembrolizumab improved event-free survival, major pathological response, and pathological complete response. The addition of pembrolizumab to neoadjuvant chemotherapy followed by surgery showed significant benefits compared to neoadjuvant chemotherapy alone followed by surgery.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Review
Pharmacology & Pharmacy
James Isaacs, Thomas E. Stinchcombe
Summary: Approximately one-third of NSCLC patients can undergo surgical resection. Neoadjuvant and adjuvant chemotherapy have been shown to improve survival outcomes. Recent trials have explored immunotherapy and targeted therapy in early-stage patients, showing improved disease-free survival.
Article
Health Care Sciences & Services
Ronald E. Myers, Shailesh M. Advani, Pamela Myers, Preethi Selvan, Gregory Garber, Brooke Worster, Neal Flomenberg, Andrew Chapman, Ralph Zinner
Summary: This study developed a novel DSI to assist NSCLC patients in treatment shared decision making, which was found to increase patient awareness of treatment options and decrease concern about treatment costs. Additional randomized controlled trials are needed to further evaluate the feasibility and efficacy of DSI implementation in clinical care.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Review
Oncology
Wen-Fang Tang, Hong-Yu Ye, Xuan Tang, Jian-Wei Su, Kang-Mei Xu, Wen-Zhao Zhong, Yi Liang
Summary: Chemotherapy is currently the standard adjuvant treatment for early-stage non-small cell lung cancer (NSCLC), but its effectiveness in improving 5-year survival rates is limited. Immunotherapy using immune checkpoint inhibitors (ICIs) has shown great potential in treating advanced NSCLC, and there is growing interest in its role in early-stage NSCLC. This article summarizes the rationale for adjuvant immunotherapy, ongoing clinical trials, and challenges in the field, and emphasizes the need for further research and validation of the role of adjuvant immunotherapy in early-stage NSCLC.
FRONTIERS IN ONCOLOGY
(2023)
Review
Oncology
Stephanie P. L. Saw, Boon-Hean Ong, Kevin L. M. Chua, Angela Takano, Daniel S. W. Tan
Summary: Despite the advancements in treatment for advanced non-small-cell lung cancer (NSCLC), there is a renewed interest in neoadjuvant strategies for early-stage NSCLC. These strategies, including targeted therapy and immunotherapy, have the potential to greatly impact survival outcomes for early-stage NSCLC patients.
Review
Oncology
Jatta Saarenheimo, Heidi Andersen, Natalja Eigeliene, Antti Jekunen
Summary: Decision-making in cancer treatment, especially in NSCLC patients, heavily relies on gene alterations, with early molecular testing of liquid biopsy samples showing increased sensitivity in detecting targetable mutations. Efforts are needed for logistics of obtaining and evaluating samples, and tissue samples should be saved for tests that are not possible from liquid biopsy.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Yangyang Xu, Bing Wan, Suhua Zhu, Tianli Zhang, Jingyuan Xie, Hongbing Liu, Ping Zhan, Tangfeng Lv, Yong Song
Summary: This study found that adjuvant chemotherapy improves survival in stage IB NSCLC patients, especially in older patients, poorly differentiated tumors, 0-15 LNs examined, VPI, lobectomy, and no radiotherapy. Further prospective trials are needed to confirm these findings. Additionally, the nomogram provides relatively accurate prediction for the prognosis of resected stage IB NSCLC patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Takefumi Komiya, Shinkichi Takamori, Gregory Wilding
Summary: This study suggests that adjuvant radiation may still play a role in improving overall survival in patients with persistent N2 disease after neoadjuvant chemotherapy. Adjuvant radiation may have a beneficial effect in patients who are not downstaged to pN0-1.
RADIOTHERAPY AND ONCOLOGY
(2022)
Article
Medicine, General & Internal
Mariano Provencio, Ernest Nadal, Jose L. Gonzalez-Larriba, Alex Martinez-Marti, Reyes Bernabe, Joaquim Bosch-Barrera, Joaquin Casal-Rubio, Virginia Calvo, Amelia Insa, Santiago Ponce, Noemi Reguart, Javier de Castro, Joaquin Mosquera, Manuel Cobo, Andres Aguilar, Guillermo Lopez Vivanco, Carlos Camps, Rafael Lopez-Castro, Teresa Moran, Isidoro Barneto, Delvys Rodriguez-Abreu, Roberto Serna-Blasco, Raquel Benitez, Carlos Aguado de la Rosa, Ramon Palmero, Florentino Hernando-Trancho, Javier Martin-Lopez, Alberto Cruz-Bermudez, Bartomeu Massuti, Atocha Romero
Summary: This study evaluated the efficacy of the neoadjuvant nivolumab plus chemotherapy regimen on operable stage III non-small-cell lung cancer (NSCLC) patients. The results showed that patients receiving the combination therapy had a higher rate of pathological complete response and longer survival, indicating the effectiveness of this treatment approach in this patient population.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Medicine, General & Internal
John V. Heymach, David Harpole, Tetsuya Mitsudomi, Janis M. Taube, Gabriella Galffy, Maximilian Hochmair, Thomas Winder, Ruslan Zukov, Gabriel Garbaos, Shugeng Gao, Hiroaki Kuroda, Gyula Ostoros, Tho V. Tran, Jian You, Kang-Yun Lee, Lorenzo Antonuzzo, Zsolt Papai-Szekely, Hiroaki Akamatsu, Bivas Biswas, Alexander Spira, Jeffrey Crawford, Ha T. Le, Mike Aperghis, Gary J. Doherty, Helen Mann, Tamer M. Fouad, Martin Reck, AEGEAN Invest
Summary: In resectable non-small-cell lung cancer patients, perioperative durvalumab plus neoadjuvant chemotherapy showed significantly improved event-free survival and pathological complete response compared to neoadjuvant chemotherapy alone, with a similar safety profile.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Review
Cardiac & Cardiovascular Systems
Jessica S. Donington, Barbara Gitlitz, Eric Lim, Isabelle Opitz, Young Tae Kim, Nasser Altorki
Summary: This review discusses the new therapeutic landscape in the adjuvant treatment of resectable non-small cell lung cancer (NSCLC) and emphasizes the role of the surgeon in ensuring optimal outcomes. Recent Phase III trials have shown significant improvements in disease-free survival with adjuvant immune checkpoint inhibitors or targeted therapy, highlighting the evolving role of the surgeon in biomarker screening and guiding adjuvant therapy.
ANNALS OF THORACIC SURGERY
(2023)
Article
Oncology
Jun-Feng Liu, Xu-Sheng Sun, Jin-Huan Yin, Xi-E Xu
Summary: This retrospective study aimed to address the effect of adjuvant chemotherapy before adjuvant EGFR-TKI therapy and the duration of EGFR-TKI therapy on survival outcomes in patients with NSCLC. The results showed that adjuvant EGFR-TKI treatment was effective for patients with stage II-IIIA EGFR-mutation positive NSCLC. Patients with stage I and pathological risk factors were also suitable for receiving adjuvant EGFR-TKI therapy.
FRONTIERS IN ONCOLOGY
(2023)
Article
Biodiversity Conservation
M. Fortnam, T. Chaigneau, L. Evans, L. Bastian
Summary: This article analyzes how practitioners consider and make trade-offs decisions when designing and implementing marine conservation development programs in Southeast Asia. They recognize both substantive and process trade-offs, and emphasize the importance of inclusive and transparent decision-making processes to improve the sustainability and legitimacy of these programs.
Article
Cardiac & Cardiovascular Systems
Scott M. Atay, Maziar Amini, Li Ding, Elizabeth A. David, P. Michael Mcfadden, Sean C. Wightman, Anthony W. Kim
Summary: The study aimed to evaluate the impact of adjuvant chemotherapy (AC) on overall survival in patients with cIIIA NSCLC who underwent curative intent surgery after neoadjuvant therapy. The results showed that AC was associated with an increase in overall survival for patients with residual pathologic lymph node involvement, while no survival benefit was seen in node-negative patients.
ANNALS OF THORACIC SURGERY
(2021)
Article
Oncology
Georgia K. B. Halkett, Elizabeth A. Lobb, Jane L. Phillips, Emma K. McDougall, Jenny Clarke, Rachel Campbell, Haryana M. Dhillon, Kevin McGeechan, Peter Hudson, Anne King, Helen Wheeler, Marina Kastelan, Anne Long, Anna K. Nowak, Care-IS Project Team
Summary: This study aimed to improve the preparedness and reduce distress of family carers through a nurse-led intervention. The complex intervention consisted of telephone assessment, resource folder, home visit, and monthly telephone support. The results showed that the intervention group had significantly higher preparedness for caregiving, but there was no difference in distress reduction.
JOURNAL OF NEURO-ONCOLOGY
(2023)
Review
Oncology
Sharyn I. Katz, Christopher M. Straus, Leonid Roshkovan, Kevin G. Blyth, Thomas Frauenfelder, Ritu R. Gill, Ferry Lalezari, Jeremy Erasmus, Anna K. Nowak, Victor H. Gerbaudo, Roslyn J. Francis, Samuel G. Armato III
Summary: This article summarizes the challenges in radiologic assessment of malignant pleural mesothelioma (MPM) and provides technical requirements and future directions for multimodal imaging.
JOURNAL OF THORACIC ONCOLOGY
(2023)
Article
Oncology
Karen Alpen, Claire M. Vajdic, Robert J. MacInnis, Roger L. Milne, Eng-Siew Koh, Elizabeth Hovey, Rosemary Harrup, Fiona Bruinsma, Tuong L. Nguyen, Shuai Li, David Joseph, Geza Benke, Pierre-Antoine Dugue, Melissa C. Southey, Graham G. Giles, Mark Rosenthal, Katharine J. Drummond, Anna K. Nowak, John L. Hopper, Miroslaw Kapuscinski, Enes Makalic
Summary: This study conducted a genome-wide association study (GWAS) on glioma in the Australian population and identified multiple genetic risk regions associated with glioma. The study also found a sex difference in the 8q24.21 region. These findings contribute to a better understanding of the etiology of glioma and have implications for prevention, risk prediction, and treatment.
Editorial Material
Respiratory System
Henry M. Marshall, Coral E. Gartner, Kwun M. Fong
Article
Clinical Neurology
Anna K. Nowak, Robert U. Newton, Travis Cruickshank, Prue Cormie, Georgia K. B. Halkett, Daphne Tsoi, Daniel A. Galvao
Summary: This study aimed to evaluate the feasibility and preliminary efficacy of supervised exercise during chemoradiotherapy for high-grade glioma patients. The results showed that only half of the patients were able to complete the exercise intervention, but for those who did, it was safe and significantly improved strength and function, potentially preventing deterioration in body composition and quality of life.
NEURO-ONCOLOGY PRACTICE
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Christian W. Wichmann, Stan Poniger, Nancy Guo, Peter Roselt, Stacey E. Rudd, Paul S. Donnelly, Benjamin Blyth, Jessica Van Zuylekom, Angela Rigopoulos, Ingrid J. G. Burvenich, Laurence Morandeau, Shifaza Mohamed, Anna K. Nowak, Fiona Hegi-Johnson, Michael MacManus, Andrew M. Scott
Summary: This study aimed to develop an automated method for the clinical production of Zr-89-labelled proteins, specifically Durvalumab, and applied it to examine PD-L1 expression dynamics. A successful conjugation of Durvalumab to H(3)DFOSqOEt resulted in H(3)DFOSq-Durvalumab with an average chelator-to-antibody ratio of 3.02. The developed automated technique was validated for clinical use at multiple study sites, highlighting its potential impact in clinical trials investigating Zr-89-labelled antibodies.
NUCLEAR MEDICINE AND BIOLOGY
(2023)
Editorial Material
Respiratory System
Edward K. H. Stephens, Henry M. M. Marshall, Venessa Chin, Kwun M. M. Fong
Article
Health Care Sciences & Services
Meera R. Agar, Anna K. Nowak, Elizabeth J. Hovey, Elizabeth H. Barnes, John Simes, Janette L. Vardy, Helen R. Wheeler, Benjamin Y. Kong, Robyn Leonard, Merryn Hall, Evonne Tim, Desma Spyridopoulos, Hao-Wen Sim, Zarnie Lwin, Anthony Dowling, Rosemary Harrup, Ross Jennens, Ganessan Kichenadasse, Tracey Dunlop, Cecelia Gzell, Eng-Siew Koh
Summary: This study aimed to determine if oral acetazolamide could safely reduce the dosage of dexamethasone used to manage raised intracranial pressure in recurrent high-grade glioma. The addition of acetazolamide did not facilitate a reduction in dexamethasone dosage.
BMJ SUPPORTIVE & PALLIATIVE CARE
(2023)
Article
Psychology, Multidisciplinary
Elizabeth A. A. Lobb, Georgia K. B. Halkett, Emma McDougall, Rachel Campbell, Haryana M. M. Dhillon, Jane L. L. Phillips, Anna K. K. Nowak
Summary: A survey of 25 caregivers of people with High Grade Glioma (HGG) revealed that one-third of them reported moderate to severe levels of anxiety, depression, and grief. The study emphasizes the importance of early and sensitive communication about prognosis, tailored information based on the disease stage, referral to psychological support services, and timely discussions about the preferred place of care and death for HGG patients.
Article
Health Care Sciences & Services
Rachel Campbell, Madeleine T. King, Martin R. Stockler, Yeh Chen Lee, Felicia T. Roncolato, Michael L. Friedlander
Summary: Patient-reported outcomes (PROs) are important in assessing symptoms and treatment effects in ovarian cancer. Well-validated PRO measures can be used in clinical trials to guide improvements in clinical practice and health policy. In clinical practice, PRO assessments can help monitor symptoms and facilitate communication between patients and their clinicians.
PATIENT-RELATED OUTCOME MEASURES
(2023)
Article
Clinical Neurology
Helen M. Haydon, Alethea Blackler, Anna K. Nowak, Danette Langbecker, Justin Collier, Georgia Halkett
Summary: An online intervention was developed to address the unmet needs of carers of people with high-grade glioma. The intervention showed high levels of usability and acceptability, and indicated a potential to decrease depression.
NEURO-ONCOLOGY PRACTICE
(2023)
Review
Clinical Neurology
Emma McDougall, Lauren J. Breen, Anna K. Nowak, Haryana M. Dhillon, Georgia K. B. Halkett
Summary: The scoping review aimed to describe the characteristics and effectiveness of psychosocial interventions for managing personality and behavior changes in individuals with brain tumors. The interventions showed improvements in targeted symptoms and outcomes for both patients and carers. However, there is a lack of available interventions in this area.
NEURO-ONCOLOGY PRACTICE
(2023)
Review
Health Care Sciences & Services
Farwa Rizvi, Helen Elizabeth Wilding, Nicole M. Rankin, Roslyn Le Gautier, Lorna Gurren, Vijaya Sundararajan, Kylee Bellingham, Joyce Chua, Gregory B. Crawford, Anna K. Nowak, Brian Le, Geoff Mitchell, Sue-Anne McLachlan, Tanara Vieira Sousa, Robyn Hudson, Maarten IJzerman, Anna Collins, Jennifer Philip
Summary: The study aimed to identify implementation frameworks used in integrated palliative care in hospital-based oncology services and describe the associated enablers and barriers to service integration. The results showed that implementation science frameworks provide support and evaluation methods for the integration of palliative care in oncology.
PALLIATIVE MEDICINE
(2023)
Article
Medicine, General & Internal
Eng-Siew Koh, Hui K. Gan, Clare Senko, Roslyn J. Francis, Martin Ebert, Sze Ting Lee, Eddie Lau, Mustafa Khasraw, Anna K. Nowak, Dale L. Bailey, Bradford A. Moffat, Greg Fitt, Rodney J. Hicks, Robert Coffey, Roel Verhaak, Kyle M. Walsh, Elizabeth H. Barnes, Richard De Abreu Lourenco, Mark Rosenthal, Lucas Adda, Farshad Foroudi, Arian Lasocki, Alisha Moore, Paul A. Thomas, Paul Roach, Michael Back, Robyn Leonard, Andrew M. Scott
Summary: FET-PET has the potential to impact adjuvant radiotherapy planning, differentiate between treatment-induced pseudoprogression and true tumor progression, and predict prognosis in glioblastoma management. The FIG study is a multicenter phase II study aiming to investigate the impact of FET-PET versus standard MRI on radiotherapy volume delineation and the accuracy and management impact of FET-PET in distinguishing pseudoprogression from true tumor progression.
Article
Health Care Sciences & Services
Ann Livingstone, Kirsten Howard, Alexander M. Menzies, Georgina V. Long, Martin R. Stockler, Rachael L. Morton
Summary: This study aimed to quantify adult preferences for adjuvant immunotherapy for resected melanoma and the influence of varying levels of key attributes and baseline characteristics. The study found that 70% of respondents chose adjuvant immunotherapy over no adjuvant immunotherapy, preferring treatment that improved efficacy and safety. The importance of this study is rated 8 out of 10.
PATIENT-PATIENT CENTERED OUTCOMES RESEARCH
(2023)